Emergency Department point-of-care antiviral host response testing is accurate during periods of multiple respiratory virus co-circulation
Description
CONCLUSIONS: In symptomatic adults FebriDx MxA had a high NPV for influenza and RSV, and retained a high NPV for SARS-CoV-2, in the context of virus co-circulation and widespread COVID-19 vaccination. FebriDx continues to be a useful 'rule out'
